[
    "**Manufacturing and Distribution**: Once a vaccine is developed and approved, it must be manufactured in large quantities and distributed to healthcare providers. This can be a logistical challenge, especially if the vaccine is a new technology or requires specialized storage conditions. Ensuring the timely and efficient distribution of the vaccine to those who need it can be a major challenge.",
    "**Cost and Affordability**: Developing a new vaccine can be expensive, and the cost of manufacturing and distributing it can be prohibitive, especially for low-income countries. This can lead to disparities in access to the vaccine, with wealthier countries able to afford it and poorer countries unable to do so.",
    "**Vaccine Hesitancy**: Even if a vaccine is developed and made widely available, there may be hesitancy among some people to get vaccinated. This can be due to concerns about the safety and efficacy of the vaccine, as well as misinformation and mistrust of the medical establishment.",
    "**Supply Chain Disruptions**: The COVID-19 pandemic has highlighted the vulnerability of global supply chains to disruptions. Any disruption in the supply chain for a new vaccine could delay its availability and impact its effectiveness in controlling the spread of the disease.",
    "**Ethical Considerations**: Developing a new vaccine may involve ethical considerations, such as ensuring that the vaccine is accessible to all people, regardless of their ability to pay. This may require government intervention or partnerships with non-profit organizations to ensure that the vaccine is made available to those who need it most."
]